Results 131 to 140 of about 16,483,910 (214)

Alantolactone inhibits T-cell lymphoma progression by suppressing CD47 expression via the PI3K/AKT and ERK signaling pathways. [PDF]

Apoptosis
Li X, Pang N, Chen Y, Pan T, Sun W, Chen B, Xie F, Mu Y, Li N.   +8 more
europepmc   +1 more source

Targeting KRAS for cancer therapy

British Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos   +4 more
wiley   +1 more source

The lncRNA PHAROH augments MYC mRNA levels in insulin-producing cells by counteracting TIA1-induced MYC silencing. [PDF]

Sci Rep
Zhao T, Welsh N.
europepmc   +1 more source

Extracellular vesicles in pharmacology: Innovations in drug delivery and therapeutic applications in cancer

British Journal of Pharmacology, EarlyView.
Extracellular vesicles (EVs) are a diverse population of membrane nanoparticles secreted by nearly all cell types, playing a key role in intercellular communication by transferring bioactive macromolecular cargo. In cancer, EVs shape both the local tumour microenvironment and distant premetastatic niches.
Evangelia Pantazaka, Georgios Sivvas, Evangelia Papadimitriou, Constantinos M. Mikelis   +3 more
wiley   +1 more source

Phase separation of ecDNA condensates establishes in-trans contact domains that boost selective MYC regulatory interactions. [PDF]

Nat Commun
Conte M, Al Hasani L, Matteuzzi T, Esposito A, Kundu S, Chiariello AM, Bianco S, Vercellone F, Li W, Nicodemi M.   +9 more
europepmc   +1 more source

Long non‐coding RNAs at the crossroads of inflammation, cancer and angiogenesis: Molecular mechanisms and their potential as therapeutic targets

British Journal of Pharmacology, EarlyView.
Long non‐coding RNAs (lncRNAs), a broad class of non‐protein‐coding RNAs, are characterized as new regulators of gene expression at the epigenetic, transcriptional, and post‐transcriptional level. Thus, lncRNAs are involved in the regulation of physiological processes and the development of human diseases and cancer by modulating proinflammatory ...
Charlie Leboff, Pamela Calle‐Mendoza, Maria Hatziapostolou, Christos Polytarchou   +3 more
wiley   +1 more source

Differential MicroRNA Expression in Chronic Spontaneous Urticaria in Relation to Treatment Response. [PDF]

Allergy Asthma Immunol Res
Lee Y, Noh JY, Yoon J, Choi B, Kim J, Woo HG, Ye YM.   +6 more
europepmc   +1 more source

Histone deacetylase inhibitors as venetoclax‐sensitising partners in acute myeloid leukaemia: Mechanisms, pharmacology and translational perspectives

British Journal of Pharmacology, EarlyView.
Abstract Venetoclax combined with hypomethylating agents has improved treatment for older or unfit patients with acute myeloid leukaemia (AML), but resistance and relapse remain common. This review analyses the rationale for combining venetoclax with inhibitors of histone deacetylase (HDAC).
Jaebok Lee, Marc Diederich
wiley   +1 more source

Evaluation of c-Myc in odontogenic cysts and tumours-An immunohistochemical study. [PDF]

J Oral Maxillofac Pathol
Pinisetti S, Vinaya NL, Adusumilli P, Babburi S, Venigalla A, Benarjee A.   +5 more
europepmc   +1 more source

Downregulation of KRTAP2‐3 Suppresses Proliferation and Tumor Formation of Oral Cancer Cells via Inactivation of KRAS Signals

Cancer Science, EarlyView.
KRTAP2‐3 drives OSCC progression by sustaining both mesenchymal and proliferative properties through KRAS signaling. Loss of KRTAP2‐3 induces MET, suppresses KRAS pathway activation, and markedly reduces tumor cell proiferation and tumor formation as illustarted in Figure.
Qianqian Miao, Zhijun Huang, Kazuki Takahashi, Haruka Ibi, Kohei Miyazono, Katarzyna A. Podyma‐Inoue, Tetsuro Watabe   +6 more
wiley   +1 more source